Development and Validation of a Novel Model to Predict Liver Histopathology in Patients with Chronic Hepatitis B

Figure 3

ROC of noninvasive biomarkers, including new ATPI model, AST-to-platelet ratio index (APRI), Fib-4 (based on age, ALT, AST, and platelet count), γ-glutamyl transpeptidase (GGT) to platelet (GPR), and HBeAg(+) model for predicting liver histopathology for commencing antiviral therapy in total patients from (a) training cohort and (d) validation cohort; patients with ALT≤2 upper limit of normal (ULN) from (b) training cohort and (e) validation cohort; patients with ALT≤ 1 ULN from (c) training cohort and (f) validation cohort.

(a)

(b)

(c)

(d)

(e)

(f)